Stock Screener App

무료 -

설치하다

12.55

0.88% 0.11

누릭스 테라퓨틱스 (NRIX)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Nurix Therapeutics Inc 주식(NRIX)의 최신 뉴스

Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO) - The Globe and Mail

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conf - GuruFocus

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

NuCana (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

(NRIX) Investment Analysis - news.stocktradersdaily.com

Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Nigeria

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges By Investing.com - Investing.com South Africa

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat

Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus

Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha

Transcript : Nurix Therapeutics, Inc.Special Call - MarketScreener

Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | NRIX Stock News - GuruFocus

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - The Manila Times

Breakthrough: Nurix Cancer Drug Achieves Complete Response in Hard-to-Treat Blood Cancers, New Trial Data Shows - Stock Titan

Nurix Therapeutics reports new KLHDC2 inhibitors - BioWorld MedTech

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail

Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com

Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus

Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph

Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat

Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat

(NRIX) On The My Stocks Page - news.stocktradersdaily.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat

Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com

Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com

Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus

Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus

Nurix secures additional $15 million from Sanofi license deal - Investing.com

Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq

Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat

Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Nurix Therapeutics to Participate in the Jefferies Global Health - GuruFocus

GMAB

$20.39

0.34%

RPRX

$36.24

0.27%

SMMT

$23.15

7.69%

INSM

$96.83

0.40%

BNTX

$108.13

0.15%

ONC

$247.47

1.13%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개